Toyohira H, Nakamura K, Kariyazono H, Yamada K, Moriyama Y, Shimokawa S, Saigenji H, Taira A
Second Department of Surgery, Faculty of Medicine Kagoshima University, Japan.
Kyobu Geka. 1995 Aug;48(9):749-55.
Patients who had undergone prosthetic valve replacement were treated with warfarin (anticoagulant) alone or in combination of ticlopidine (200 mg/day) or aspirin (81 mg/day) (anti-platelet agents). The study of blood coagulation factors and platelet aggregation were carried out with these cases. 1) The patients (n = 24) receiving warfarin for 21 days after prosthetic valve replacement revealed marked increases in PIVKA-II and vitamin K1-epoxide. The protein C activity was significantly lower than that before the operation. High levels of more than 5 ng/ml of TAT were found before operation and after warfarin administration for 21 days. 2) Warfarin did not affect platelet aggregation, whereas ticlopidine inhibited ADP-induced platelet aggregation and aspirin inhibited both collagen-induced and arachidonic acid-induced aggregation. In conclusion, combined use of anticoagulants and antiplatelet agents after prosthetic valve replacement will suppress not only the blood coagulation but also the platelet aggregation systems.
接受人工瓣膜置换术的患者单独使用华法林(抗凝剂)治疗,或联合使用噻氯匹定(200毫克/天)或阿司匹林(81毫克/天)(抗血小板药物)治疗。对这些病例进行了凝血因子和血小板聚集的研究。1)人工瓣膜置换术后接受华法林治疗21天的患者(n = 24)显示,异常凝血酶原-II和维生素K1-环氧化物显著增加。蛋白C活性明显低于手术前。术前和华法林给药21天后发现凝血酶-抗凝血酶复合物水平高于5纳克/毫升。2)华法林不影响血小板聚集,而噻氯匹定抑制二磷酸腺苷诱导的血小板聚集,阿司匹林抑制胶原诱导和花生四烯酸诱导的聚集。总之,人工瓣膜置换术后联合使用抗凝剂和抗血小板药物不仅会抑制凝血系统,还会抑制血小板聚集系统。